Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Epidermal Growth Factor Receptor
86%
Lung Cancer
85%
Chemotherapy
48%
Immune Checkpoint Inhibitor
30%
Epidermal Growth Factor Receptor Kinase Inhibitor
30%
Osimertinib
27%
Progression Free Survival
27%
Granulocyte Colony Stimulating Factor
26%
Overall Survival
25%
Gefitinib
23%
Malignant Neoplasm
20%
Neoplasm
19%
Afatinib
16%
Group Trial
15%
Protein Tyrosine Kinase Inhibitor
14%
Anaplastic Lymphoma Kinase
12%
Pembrolizumab
12%
Chemoradiation Therapy
11%
Disease
10%
Monotherapy
10%
Adverse Event
10%
Alectinib
10%
Lung Adenocarcinoma
10%
Febrile Neutropenia
9%
Cisplatin
9%
Disease Exacerbation
9%
Bevacizumab
7%
Transgenic Mouse
7%
Lung Tumor
7%
Combination Therapy
7%
Small Cell Lung Cancer
7%
Carboplatin
7%
Cancer Model
7%
Observational Study
6%
Vandetanib
6%
Infection
6%
Protein Tyrosine Kinase
6%
Erlotinib
6%
Diseases
6%
Pemetrexed
5%
Interstitial Lung Disease
5%
Programmed Cell Death
5%
Phase II Trials
5%
Randomized Controlled Trial
5%
Median Survival Time
5%
Pleura Effusion
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
39%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
27%
Epidermal Growth Factor Receptor
24%
Lung Cancer
24%
Immune Checkpoint Inhibitors
22%
EGFR mutation
18%
Chemotherapy
17%
Osimertinib
16%
Okayama
15%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
14%
Cancer Study
14%
Non-small Cell Lung Cancer Patients
13%
Clinical Practice Guidelines
13%
Granulocyte Colony-stimulating Factor (G-CSF)
13%
Progression-free Survival
11%
Gefitinib
11%
Primary Prophylaxis
10%
T790M
10%
Afatinib
9%
Poor Performance Status
8%
Overall Survival
8%
Lung Adenocarcinoma
8%
Re-biopsy
8%
Re-administration
7%
Bevacizumab
6%
Programmed Death-ligand 1 (PD-L1)
6%
Japan Society of Clinical Oncology
6%
Tumor
6%
Performance Status
6%
Median Progression-free Survival
5%
Pembrolizumab
5%
Nave
5%
Tyrosine Kinase Inhibitor
5%
Interstitial Lung Disease
5%
Confidence Interval
5%
Meta-analysis
5%
Antibiotics
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
58%
Lung Cancer
41%
Epidermal Growth Factor Receptor
33%
Systematic Review
22%
Granulocyte Colony Stimulating Factor
22%
Immune Checkpoint Inhibitor
19%
Clinical Oncology
15%
Neoplasm
14%
Meta-Analysis
14%
Lung Adenocarcinoma
13%
Pembrolizumab
10%
Progression Free Survival
10%
Overall Survival
9%
COVID-19
9%
Exon
9%
Cisplatin
9%
Computer Assisted Tomography
9%
Febrile Neutropenia
8%
Tyrosine-Kinase Inhibitor
8%
Osimertinib
7%
Programmed Death 1 Ligand 1
7%
Gefitinib
7%
Chemoradiotherapy
6%
Nivolumab
5%
Anaplastic Lymphoma Kinase
5%
Alectinib
5%
Biopsy
5%
Adenocarcinoma
5%
Disease Exacerbation
5%
Epidermal Growth Factor Receptor Kinase Inhibitor
5%
Pemetrexed
5%
Programmed Cell Death
5%
Nephrotoxicity
5%
